# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	ırden
houre por roeponeo	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Nama an															
1. Name and Address of Reporting Person * PAYAN DONALD G			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						<u> </u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director 10% Owner					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC, ,, 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 02/01/2011						X Officer (give title below) Other (specify below)  EVP, Pres. Discovery&Research					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						es Acquire	ured, Disposed of, or Beneficially Owned				
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution D any (Month/Day		ate, if C	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities		d (	Ownership of Borm:	Nature Indirect eneficial wnership	
							Code	e V A	(A) or (D)	Price			(	or Indirect (Ir I) (Instr. 4)	nstr. 4)
Reminder:	Report on a s	separate fine for each	i ciass of securities		, 0			in this f	s who respor orm are not r s a currently	equired t	o respond	unless the		ed SEC 14	74 (9-02)
Reminder:	Report on a s	reparate fine for each		· Derivat	ive Se	ecurities	Acqui	in this t display	orm are not rest a currently osed of, or Ben	equired to valid OMI eficially Ov	o respond B control r	unless the		ed SEC 14	74 (9-02)
1. Title of	2. Conversion or Exercise Price of	3. Transaction	Table II -  3A. Deemed Execution Date, if	Derivat (e.g., pu 4. Transac Code	ive Setts, cal	ecurities Ils, warr 5. Numb of Deriva Securitie Acquired	Acquirants, of the set	in this t display dired, Dispo options, co	orm are not rest a currently osed of, or Benonvertible securicisable and Date	equired to valid OMI eficially Overities)	o respond B control r wned and Amount lying	8. Price of	9. Number o Derivative Securities Beneficially	f 10. Ownership Form of Derivative	11. Natur of Indirec Beneficia Ownersh
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction	Table II -  3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transac Code	ive Setts, cal	ecurities Ils, warr 5. Numb of Deriva Securitie	a Acquirants, or antive I (at (A) (best) (continued at (A) (best) (cont	in this to display tired, Dispositions, confictions, confictions, confiction in the second se	orm are not rest a currently osed of, or Benonvertible securicisable and Date	equired to valid OMI eficially Ovities)  7. Title are of Underly Securities	o respond B control r wned and Amount lying	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported Transaction(	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indired Beneficia
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II -  3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transac Code	ive Setts, cal	ecurities Ils, warr 5. Numb of Deriv. Securitie Acquirec or Dispo of (D) (Instr. 3,	Acquirants, or for an article is (i.e., i.e., i.	in this to display tired, Dispositions, confictions, confictions, confiction in the second se	orm are not rest a currently osed of, or Benenvertible securicisable and Date y/Year)	equired to valid OMI eficially Ovities)  7. Title are of Underly Securities	o respond B control r wned and Amount lying	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirect Beneficia Ownersh

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
PAYAN DONALD G RIGEL PHARMACEUTICALS, INC, , 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		EVP, Pres. Discovery&Research			

## **Signatures**

/s/Dolly Vance (Attorney-in-Fact)	02/02/2011
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vests monthly over one (1) year from January 1, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.